

Commissioner for Patents  
August 9, 2006  
Page 2

RECEIVED  
CENTRAL FAX CENTER  
AUG 09 2006

### CLAIMS

1. (Presently Amended) A method for treating a patient having a spinal cord injury, the method comprising:

electrically stimulating the site of the spinal cord injury through the use of oscillating field stimulation; and

administering a purine nucleoside ~~or analog thereof~~ to the patient;

wherein nerve function through said injured spinal cord is at least partially restored.

2. (Presently Amended) The method of claim 1 further comprising implanting a device into the patient, which device electrically stimulates the site of the spinal cord injury with oscillating field stimulation.

3. (Cancelled) The method of claim 2 wherein the device is an oscillating field stimulation device.

4. (Original) The method of claim 1 wherein the purine nucleoside comprises inosine.

5. (Presently Amended) The method of claim 1 wherein the purine nucleoside ~~or analog thereof~~ is administered to the patient systemically or locally.

6. (Presently Amended) The method of claim 1 wherein the purine nucleoside ~~or analog thereof~~ is administered orally, transdermally, interperitoneally, intravenously, or subcutaneously.

7. (Cancelled) The method of claim 1 wherein the purine nucleoside or analog thereof is administered locally to the site of the spinal cord injury.

8. (Presently Amended) The method of claim ~~7~~ 1 further comprising implanting a device into the patient, which device locally administers the purine nucleoside ~~or analog thereof~~.

Commissioner for Patents  
August 9, 2006  
Page 3

9. (Presently Amended) The method of claim 1 wherein the spinal cord injury occurred more than 100 hours ~~three months~~ prior to the treatment.

10. (Original) The method of claim 1 wherein the patient is human.

11. (Original) The method of claim 1 wherein the patient is a domestic pet.

12. (Previously Amended) The method of claim 1 wherein said restoration of nerve function is evidenced by restoration of nerve impulse conduction, a detectable increase in conduction action potentials, observation of anatomical continuity, restoration of more than one spinal root level, an increase in reflex behavior, or combinations thereof.

13. (Presently Amended) A method for treating a patient having a spinal cord injury, the method comprising:

electrically stimulating the site of ~~the~~ a chronic spinal cord injury through the use of oscillating field stimulation; and

administering a purine nucleoside ~~or analog thereof~~ to the patient; wherein nerve regeneration at the site of the chronic spinal cord injury is stimulated.

14. (Cancelled) A method for treating a patient having a spinal cord injury, the method comprising administering to the patient a purine nucleoside or analog thereof under conditions effective to restore nerve function through said injured spinal cord.

15. (Cancelled) A method for treating a patient having a spinal cord injury, the method comprising administering to the patient a purine nucleoside or analog thereof under conditions effective to stimulate nerve regeneration at the site of the spinal cord injury.

16. (Cancelled) A kit for the treatment of a central nervous system injury, the kit comprising a means for the application of an electrical stimulation to the injury site and a purine nucleoside or analog thereof.

Commissioner for Patents  
August 9, 2006  
Page 4

17. (Cancelled) The kit of claim 16, wherein the means for the application of an electrical stimulation to the injury site comprises an oscillating field stimulation device and the purine nucleoside or analog thereof comprises inosine.

18. (Cancelled) The kit of claim 16, further comprising a device for subcutaneous, intravenous, or intrathecal deliver of the purine nucleoside or analog thereof.

19. (Cancelled) The kit of claim 16, further comprising written instructions for the treatment of a central nervous system injury.

20. (New) The method of claim 9, wherein the spinal cord injury occurred more than three months prior to the treatment prior to the treatment.

21. (New) The method of claim 13, wherein the purine nucleoside is inosine, guanine, adenine, or 6-thioguanine.

22. (New) The method of claim 13, wherein the step of administering a purine nucleoside occurs more than 100 hours after the spinal cord injury occurs.

23. (New) The method of claim 22, wherein the step of electrically stimulating the site of a chronic injury occurs more than three weeks after the spinal cord injury occurs.

24. (New) The method of claim 13, wherein the step of administering oscillating field stimulation to the patient coincides with a time when the administered purine nucleoside is present in the patient.

25. (New) A method for treating a spinal cord injury, the method comprising the steps of:

administering inosine to a patient wherein the administering first occurs more than 100 hours after occurrence of the spinal cord injury and does not comprise intrathecal administration; and

Commissioner for Patents  
August 9, 2006  
Page 5

administering oscillating field stimulation to the patient more than three weeks after occurrence of the spinal cord injury, wherein nerve growth is initiated.

26. (New) The method of claim 25, wherein the spinal cord injury is a chronic injury.

27. (New) The method of claim 25, wherein the step of administering inosine further involves the use of a pharmaceutical carrier selected from the group consisting of water, lactated ringers solution, polyethylene glycol, or slow release capsules as a carrier for the inosine.

28. (New) The method of claim 25, wherein the step of administering oscillating field stimulation to the patient occurs during a time when the administered purine nucleoside is present in the patient.

29. (New) The method of claim 28, wherein the step of administering oscillating field stimulation to the patient approximately coincides with the step of administering inosine to the patient.